Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome

John W. Huggins, Chin Min Hsiang, Thomas M. Cosgriff, Mei Ying Guang, Joseph I. Smith, Zhen Ou Wu, James LeDuc, Zhi Ming Zheng, James M. Meegan, Qi Nan Wang, Dwayne D. Oland, Xi En Gui, Paul H. Gibbs, Guang Hui Yuan, Tian Ming Zhang

Research output: Contribution to journalArticle

304 Citations (Scopus)

Abstract

A prospective, randomized, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days) was conducted in 242 patients with serologically confirmed hemorrhagic fever with renal syndrome (HFRS) in the People's Republic of China. Mortality was significantly reduced (sevenfold decrease in risk) among ribavirin-treated patients, when comparisons were adjusted for baseline risk estimators of mortality (P = .01; two-tailed). HFRS typically consists of five consecutive but frequently overlapping clinical phases. Only occurrence of oliguric phase and hemorrhage was associated with severity of clinical disease in the placebo group. Ribavirin therapy also resulted in a significant reduction in the risk of entering the oliguric phase and experiencing hemorrhage. The only ribavirin-related side effect was a well-recognized, fully reversible anemia after completion of therapy.

Original languageEnglish (US)
Pages (from-to)1119-1127
Number of pages9
JournalJournal of Infectious Diseases
Volume164
Issue number6
StatePublished - Dec 1991
Externally publishedYes

Fingerprint

Hemorrhagic Fever with Renal Syndrome
Ribavirin
Controlled Clinical Trials
Placebos
Hemorrhage
Mortality
Risk Reduction Behavior
Therapeutics
Anemia
China

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Huggins, J. W., Hsiang, C. M., Cosgriff, T. M., Guang, M. Y., Smith, J. I., Wu, Z. O., ... Zhang, T. M. (1991). Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. Journal of Infectious Diseases, 164(6), 1119-1127.

Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. / Huggins, John W.; Hsiang, Chin Min; Cosgriff, Thomas M.; Guang, Mei Ying; Smith, Joseph I.; Wu, Zhen Ou; LeDuc, James; Zheng, Zhi Ming; Meegan, James M.; Wang, Qi Nan; Oland, Dwayne D.; Gui, Xi En; Gibbs, Paul H.; Yuan, Guang Hui; Zhang, Tian Ming.

In: Journal of Infectious Diseases, Vol. 164, No. 6, 12.1991, p. 1119-1127.

Research output: Contribution to journalArticle

Huggins, JW, Hsiang, CM, Cosgriff, TM, Guang, MY, Smith, JI, Wu, ZO, LeDuc, J, Zheng, ZM, Meegan, JM, Wang, QN, Oland, DD, Gui, XE, Gibbs, PH, Yuan, GH & Zhang, TM 1991, 'Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome', Journal of Infectious Diseases, vol. 164, no. 6, pp. 1119-1127.
Huggins, John W. ; Hsiang, Chin Min ; Cosgriff, Thomas M. ; Guang, Mei Ying ; Smith, Joseph I. ; Wu, Zhen Ou ; LeDuc, James ; Zheng, Zhi Ming ; Meegan, James M. ; Wang, Qi Nan ; Oland, Dwayne D. ; Gui, Xi En ; Gibbs, Paul H. ; Yuan, Guang Hui ; Zhang, Tian Ming. / Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. In: Journal of Infectious Diseases. 1991 ; Vol. 164, No. 6. pp. 1119-1127.
@article{539cda56581448acae4140bf358c5c3f,
title = "Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome",
abstract = "A prospective, randomized, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days) was conducted in 242 patients with serologically confirmed hemorrhagic fever with renal syndrome (HFRS) in the People's Republic of China. Mortality was significantly reduced (sevenfold decrease in risk) among ribavirin-treated patients, when comparisons were adjusted for baseline risk estimators of mortality (P = .01; two-tailed). HFRS typically consists of five consecutive but frequently overlapping clinical phases. Only occurrence of oliguric phase and hemorrhage was associated with severity of clinical disease in the placebo group. Ribavirin therapy also resulted in a significant reduction in the risk of entering the oliguric phase and experiencing hemorrhage. The only ribavirin-related side effect was a well-recognized, fully reversible anemia after completion of therapy.",
author = "Huggins, {John W.} and Hsiang, {Chin Min} and Cosgriff, {Thomas M.} and Guang, {Mei Ying} and Smith, {Joseph I.} and Wu, {Zhen Ou} and James LeDuc and Zheng, {Zhi Ming} and Meegan, {James M.} and Wang, {Qi Nan} and Oland, {Dwayne D.} and Gui, {Xi En} and Gibbs, {Paul H.} and Yuan, {Guang Hui} and Zhang, {Tian Ming}",
year = "1991",
month = "12",
language = "English (US)",
volume = "164",
pages = "1119--1127",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome

AU - Huggins, John W.

AU - Hsiang, Chin Min

AU - Cosgriff, Thomas M.

AU - Guang, Mei Ying

AU - Smith, Joseph I.

AU - Wu, Zhen Ou

AU - LeDuc, James

AU - Zheng, Zhi Ming

AU - Meegan, James M.

AU - Wang, Qi Nan

AU - Oland, Dwayne D.

AU - Gui, Xi En

AU - Gibbs, Paul H.

AU - Yuan, Guang Hui

AU - Zhang, Tian Ming

PY - 1991/12

Y1 - 1991/12

N2 - A prospective, randomized, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days) was conducted in 242 patients with serologically confirmed hemorrhagic fever with renal syndrome (HFRS) in the People's Republic of China. Mortality was significantly reduced (sevenfold decrease in risk) among ribavirin-treated patients, when comparisons were adjusted for baseline risk estimators of mortality (P = .01; two-tailed). HFRS typically consists of five consecutive but frequently overlapping clinical phases. Only occurrence of oliguric phase and hemorrhage was associated with severity of clinical disease in the placebo group. Ribavirin therapy also resulted in a significant reduction in the risk of entering the oliguric phase and experiencing hemorrhage. The only ribavirin-related side effect was a well-recognized, fully reversible anemia after completion of therapy.

AB - A prospective, randomized, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days) was conducted in 242 patients with serologically confirmed hemorrhagic fever with renal syndrome (HFRS) in the People's Republic of China. Mortality was significantly reduced (sevenfold decrease in risk) among ribavirin-treated patients, when comparisons were adjusted for baseline risk estimators of mortality (P = .01; two-tailed). HFRS typically consists of five consecutive but frequently overlapping clinical phases. Only occurrence of oliguric phase and hemorrhage was associated with severity of clinical disease in the placebo group. Ribavirin therapy also resulted in a significant reduction in the risk of entering the oliguric phase and experiencing hemorrhage. The only ribavirin-related side effect was a well-recognized, fully reversible anemia after completion of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025838388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025838388&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 1119

EP - 1127

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -